| Overview |
| bs-14651R-Cy7 |
| EVPLL Polyclonal Antibody, Cy7 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Specifications |
| Cy7 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human EVPLL |
| 101-200/301 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 645027 |
| A8MZ36 |
| Cytoplasm, Cell membrane |
| Envoplakin like; Envoplakin-like protein; EVPLL; EVPLL_HUMAN; |
| EVPLL (envoplakin-like protein) is a 301 amino acid protein that belongs to the plakin or cytolinker family. The gene encoding EVPLL maps to human chromosome 17, which comprises over 2.5% of the human genome and encodes over 1,200 genes. Two key tumor suppressor genes are associated with chromosome 17, namely, p53 and BRCA1. Tumor suppressor p53 is necessary for maintenance of cellular genetic integrity by moderating cell fate through DNA repair versus cell death. Malfunction or loss of p53 expression is associated with malignant cell growth and Li-Fraumeni syndrome. Like p53, BRCA1 is directly involved in DNA repair, though specifically it is recognized as a genetic determinant of early onset breast cancer and predisposition to cancers of the ovary, colon, prostate gland and fallopian tubes. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz